| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Beyza Nur Karal, Yahya Esad Özdemir, Ali Karayağmurl. The Management of Very Early-Onset Schizophrenia With an Olanzapine and Amisulpride Combination. Journal of clinical psychopharmacology. 2024-05-02. PMID:38695720. |
the management of very early-onset schizophrenia with an olanzapine and amisulpride combination. |
2024-05-02 |
2024-05-04 |
Not clear |
| Jin-Ling Liu, Zhi-Mei Tan, Shu-Jie Jia. Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia. World journal of psychiatry. vol 13. issue 7. 2023-08-07. PMID:37547736. |
repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia. |
2023-08-07 |
2023-08-14 |
Not clear |
| Stefan Leucht, Johannes Schneider-Thoma, Angelika Burschinski, Natalie Peter, Dongfang Wang, Shimeng Dong, Maximilian Huhn, Adriani Nikolakopoulou, Georgia Salanti, John M Davi. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World psychiatry : official journal of the World Psychiatric Association (WPA). vol 22. issue 2. 2023-05-10. PMID:37159349. |
concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% ci: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% ci: -3.35 to -1.25) compared to amisulpride. |
2023-05-10 |
2023-08-14 |
human |
| Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnse. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro). Journal of clinical psychopharmacology. 2023-04-21. PMID:37083542. |
antidepressive effectiveness of amisulpride, aripiprazole, and olanzapine in patients with schizophrenia spectrum disorders: a secondary outcome analysis of a pragmatic, randomized trial (best intro). |
2023-04-21 |
2023-08-14 |
Not clear |
| Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnse. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro). Journal of clinical psychopharmacology. 2023-04-21. PMID:37083542. |
amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. |
2023-04-21 |
2023-08-14 |
Not clear |
| Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnse. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro). Journal of clinical psychopharmacology. 2023-04-21. PMID:37083542. |
consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the calgary depression scale for schizophrenia sum score in patients within the schizophrenia spectrum. |
2023-04-21 |
2023-08-14 |
Not clear |
| Young Sup Woo, Sung-Yong Park, Bo-Hyun Yoon, Won-Seok Choi, Sheng-Min Wang, Won-Myong Bah. Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 3. 2022-07-25. PMID:35879041. |
amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, rater-blind, controlled, pilot study. |
2022-07-25 |
2023-08-14 |
Not clear |
| Stephan Heres, Joachim Cordes, Sandra Feyerabend, Christian Schmidt-Kraepelin, Richard Musil, Michael Riedel, Ilja Spellmann, Berthold Langguth, Michael Landgrebe, Elmar Fran, Camelia Petcu C, Eric Hahn, Tam M T Ta, Valentin Matei, Liana Dehelean, Ion Papava, F Markus Leweke, Till van der List, Simona C Tamasan, Fabian U Lang, Dieter Naber, Stephan Ruhrmann, Claus Wolff-Menzler, Georg Juckel, Maria Ladea, Cristinel Stefanescu, Marion Lautenschlager, Michael Bauer, Daisy Zamora, Mark Horowitz, John M Davis, Stefan Leuch. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. Schizophrenia bulletin. 2022-07-20. PMID:35857811. |
changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia. |
2022-07-20 |
2023-08-14 |
Not clear |
| N Mørkved, E Johnsen, R A Kroken, D Winje, T K Larsen, J C Thimm, M A Rettenbacher, C A Bartz Johannesen, E-M Løber. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial. Schizophrenia research. vol 246. 2022-06-16. PMID:35709647. |
the present study aimed to investigate symptom change (the positive and negative syndrome scale) from baseline to 1, 3, 6, 12, 26, 39 and 52 weeks of antipsychotic treatment (amisulpride, aripiprazole and olanzapine) by group (ct/no ct). |
2022-06-16 |
2023-08-14 |
human |
| N Mørkved, E Johnsen, R A Kroken, D Winje, T K Larsen, J C Thimm, M A Rettenbacher, C A Bartz Johannesen, E-M Løber. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial. Schizophrenia research. vol 246. 2022-06-16. PMID:35709647. |
participants (n = 98) with diagnoses within the schizophrenia spectrum (f20-29 in the international classification of diseases - 10th revision) were randomized to receive amisulpride, aripiprazole or olanzapine, and for this study categorized into groups of none and low ct, and moderate to severe ct according to thresholds defined by the childhood trauma questionnaire short-form manual. |
2022-06-16 |
2023-08-14 |
human |
| Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Pablo-Emilio Verde, Christoph U Correll, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm B Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Stefan Leucht, Joachim Corde. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. The lancet. Psychiatry. 2022-03-11. PMID:35276079. |
amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in germany (combine): a double-blind randomised controlled trial. |
2022-03-11 |
2023-08-13 |
Not clear |
| Yingjie Qi, Guangxuan Li. Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Determination of Antipsychotic Drugs in Human Plasma and Its Application in Therapeutic Drug Monitoring. Drug design, development and therapy. vol 15. 2021-10-08. PMID:33613026. |
we developed and validated an ultra-performance liquid chromatography-tandem mass spectrometry (uplc-ms/ms) method for simultaneous therapeutic drug monitoring (tdm) and clinical pharmacokinetic antipsychotic drugs: clozapine (clp), chlorpromazine (cpz), risperidone (rpd), paliperidone (pld), quetiapine (qtp;), aripiprazole (apz), dehydroaripiprazole (dap), olanzapine (ozp), ziprasidone (zrd), and amisulpride (asp). |
2021-10-08 |
2023-08-13 |
human |
| Liss Anda, Erik Johnsen, Rune A Kroken, Inge Joa, Maria Rettenbacher, Else-Marie Løber. Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT. Schizophrenia research. Cognition. vol 26. 2021-07-15. PMID:34258237. |
this pragmatic, semi-randomized, industry-independent study aimed to investigate and compare the effect of amisulpride, aripiprazole and olanzapine on cognitive performance in psychosis over a 12-month period controlling for diagnostic group. |
2021-07-15 |
2023-08-13 |
Not clear |
| Igne Sinkeviciute, Kenneth Hugdahl, Christoffer Bartz-Johannessen, Rune Andreas Kroken, Else-Marie Løberg, Eirik Kjelby, Maria Anna Rettenbacher, Inge Joa, Solveig Klæbo Reitan, Renata Alisauskiene, Farivar Fathian, Erik Johnse. Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial. Journal of clinical psychopharmacology. vol 41. issue 4. 2021-07-07. PMID:33938520. |
studies focusing on a separate symptom, such as hallucinations, a hallmark symptom in schizophrenia, are scarce.therefore, the current study aims to compare the antihallucinatory effectiveness of 3 pharmacologically different antipsychotics: olanzapine, amisulpride, and aripiprazole. |
2021-07-07 |
2023-08-13 |
Not clear |
| Daniel Prates Baldez, Tais Boeira Biazus, Francisco Diego Rabelo-da-Ponte, Guilherme Pedro Nogaro, Dayane Santos Martins, Maurício Kunz, Letícia Sanguinetti Czepielewsk. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. Neuroscience and biobehavioral reviews. vol 126. 2021-06-28. PMID:33812977. |
compared to other antipsychotics, amisulpride performed better on verbal learning; quetiapine on composite score, attention and verbal learning; lurasidone on composite score; olanzapine on composite score and most cognitive domains; perphenazine on composite score, executive function, working memory, and verbal learning; risperidone on executive function and verbal learning; sertindole on processing speed; and ziprasidone on composite score, working memory, and verbal learning. |
2021-06-28 |
2023-08-13 |
Not clear |
| Alexander Kiss, Jana Osack. c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences. Endocrine regulations. vol 54. issue 1. 2021-04-02. PMID:32597143. |
c-fos and fosb/Δfosb colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences. |
2021-04-02 |
2023-08-13 |
rat |
| Alexander Kiss, Jana Osack. c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences. Endocrine regulations. vol 54. issue 1. 2021-04-02. PMID:32597143. |
olanzapine (ola), amisulpride (ami), aripiprazole (ari), and quetiapine (que) belong to antipsychotics, which administration represents still most reliable way for the treatment of schizophrenic and bipolar disorders. |
2021-04-02 |
2023-08-13 |
rat |
| Alexander Kiss, Jana Osack. Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus. Endocrine regulations. vol 54. issue 2. 2021-04-02. PMID:32597151. |
effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus. |
2021-04-02 |
2023-08-13 |
rat |
| Alexander Kiss, Jana Osack. Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus. Endocrine regulations. vol 54. issue 2. 2021-04-02. PMID:32597151. |
the goal of this study was to reveal the impact of four types of atypical antipsychotics including amisulpride (ami), olanzapine (ola), quetiapine (que), and aripiprazole (ari), with different receptor-affinity profile and dissociation constant, on the activity of hypothalamic supraoptic nucleus (son) vasopressinergic and oxytocinergic neurons. |
2021-04-02 |
2023-08-13 |
rat |
| Zhan-Miao Yi, Peng Men, Shuli Qu, Chaoyun Li, Xin Yu, Suodi Zha. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research. vol 20. issue 3. 2021-01-22. PMID:32293194. |
comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in china. |
2021-01-22 |
2023-08-13 |
Not clear |